April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Corneal Thickness Changes and Results of Collagen Crosslinking using Riboflavin/Dextran or Hypotonic Riboflavin.
Author Affiliations & Notes
  • Elan Aaron Rosenblat
    Department of Ophthalmology, Inst of Ophthalmology and Visual Science Rutgers University, Newark, NY
  • Steven A Greenstein
    Department of Ophthalmology, Inst of Ophthalmology and Visual Science Rutgers University, Newark, NY
  • Peter S Hersh
    Department of Ophthalmology, Inst of Ophthalmology and Visual Science Rutgers University, Newark, NY
  • Footnotes
    Commercial Relationships Elan Rosenblat, None; Steven Greenstein, None; Peter Hersh, Avedro, Inc (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4223. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elan Aaron Rosenblat, Steven A Greenstein, Peter S Hersh; Corneal Thickness Changes and Results of Collagen Crosslinking using Riboflavin/Dextran or Hypotonic Riboflavin.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4223.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

This study was designed to compare the use of two riboflavin formulations, riboflavin 0.1% in 20% dextran solution and its hypotonic formulation without dextran with regard to intraoperative corneal thinning and clinical results.

 
Methods
 

63 eyes with keratoconus and corneal ectasia were analyzed in a prospective randomized control clinical trial. Both arms of the study received pretreatment with riboflavin 0.1% in 20% dextran solution; one drop was administered every 2 minutes for 30 minutes after the corneal epithelium was removed. If the corneal thickness was less than 400µm hypotonic riboflavin was administered until the cornea swelled beyond 400µm. Both study groups then received 30 minutes exposure to UV light (365 micron wavelength, irradiance 3mW/cm2). During UV exposure, eyes received continued riboflavin application, the formulation of which was assigned by 2 randomized study arms: 35 patients received riboflavin/dextran and 28 patients received hypotonic riboflavin every 2 minutes for the duration of UV exposure. Corneal thickness measurements were then analyzed between both arms of the study. Pachymetry was measured by ultrasound before the corneal epithelium was removed, after initial riboflavin loading prior to, and after UV light exposure. At least 5 pachymetry measurements were taken at each time point and the lowest used for analysis. Patients were then followed at 1, 3, 6 and 12 months postoperatively. If any patient missed an appointment they were removed from the study. Thirty nine patients with either keratoconus (29) or post lasik ectasia (10) who underwent corneal cross-linking remained in the study. 21 patients (15 keratoconus, 6 ectasia) received standard riboflavin dextran solution during UVA light administration and 18 patients (14 keratoconus, 4 ectasia) received a hypotonic riboflavin solution during UVA light administration.

 
Results
 

Please see attached Figures.

 
Conclusions
 

The cornea thins substantially during the collagen crosslinking procedure. The use of hypotonic riboflavin rather than riboflavin/dextran during UV administration decreases the amount of corneal thinning during the procedure 24%, from thinning of 135 microns to 102 microns. These intraoperative changes were transient and there were no statistically significant difference in outcomes at 1, 3,6, or 12 month followup.

     
Keywords: 574 keratoconus • 479 cornea: clinical science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×